Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
8
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
8
×
biotech
fda
clinical trials
new york blog main
new york top stories
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
drugs
hereditary transthyretin amyloidosis
inotersen
patisiran
roche
san diego blog main
san diego top stories
tafamidis
avapritinib
blueprint medicines
deals
eli lilly
europe blog main
europe top stories
european medicines agency
genentech
medullary thyroid cancer
non-small cell lung cancer
onpattro
pfizer
postpartum depression
pralsetinib
rna interference
sage therapeutics
selpercatinib
What
fda
8
×
drug
medicine
approval
alnylam
rna
approved
approves
blueprint
cancer
depression
gene
historic
hits
medicines
ret
rnai
roche
specifically
therapeutics
therapy
uses
address
afternoon
ago
alnylam’s
approve
awaits
betting
billion
biological
biopharma
brexanalone
brexanolone
candidate
carries
cells
certain
crossed
currently
Language
unset
Current search:
boston
×
fda
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision